Trametinib was described to decrease the number of cells in the synthesis phase in BRAF-mutant lung cancer cells [24], and to induce G1 cell cycle arrest and apoptosis in RAS- and RAF-mutated melanoma cells [25,26]. This evidence concerns the gene BRAF and lung carcinoma.